# The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease

> **NCT06606821** · PHASE4 · RECRUITING · sponsor: **Tina Vilsbøll** · enrollment: 124 (estimated)

## Conditions studied

- Coronary Artery Disease
- Coronary Microvascular Dysfunction
- Overweight or Obesity
- Stable Angina Pectoris
- Chronic Coronary Artery Disease
- Atherosclerosis Cardiovascular Disease

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06606821
- **Lead sponsor:** Tina Vilsbøll
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-01
- **Primary completion:** 2027-03-20
- **Final completion:** 2028-08-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2025-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06606821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06606821, "The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06606821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*